Dialogue & Opinion (IGR: 26-1) | International Glaucoma Review

Dialogue & Opinion all issues

Where the glaucoma community argues it out: 187 Dialogue comments and 27 Opinion pieces, newest first.

In a Dialogue several experts comment on the same paper and the authors are invited to respond. An Opinion is a single invited viewpoint.

IGR 25-1 | 2025

On: Virtual Reality Visual Perceptual Plastic Training Promotes Retinal Structure and Macular Function Recovery in Glaucoma Patients

Comment Harry Quigley Comment Chris Johnson Comment Giovanni Montesano
Extraordinary claims require extraordinary evidence

IGR 24-1/2 | 2024

On: Sustained Vision Recovery by OSK Gene Therapy in a Mouse Model of Glaucoma

Comment Harry Quigley Comment Derek Welsbie Comment Pete Williams Response David Sinclair & Bruce Ksander

IGR 22-1 | 2021

On: Impaired TRPV4-eNOS signaling in trabecular meshwork elevates intraocular pressure in glaucoma

Comment Heather McGowan & Louis Pasquale Comment Darryl Overby & Daniel Stamer Response Pinkal Patel & Gulab Zode & Swapnil Sonkusare

IGR 21-2 | 2021

On: Reprogramming to recover youthful epigenetic information and restore vision

Comment Keith Martin Comment Harry Quigley Comment Dorota Skowronska-Krawczyk Comment Derek Welsbie

IGR 21-1 | 2020

Opinion Defining glaucomatous optic neuropathy using objective criteria from structural and functional testing. Iyer JV, Boland MV, Jefferys J, Quigley H. Bri… IGR 21-1 | 2020

IGR 20-4 | 2020

On: Review of hygiene and disinfection Recommendations for outpatient glaucoma care: A COVID era update

Comment Ningli Wang & Chunyan Qiao Comment Luciano Quaranta Comment Poemen Chan & Clement Tham Comment Brandon J. Wong Comment Tin Aung & Rahat Husain Comment Pradeep Ramulu Comment Michele C. Lim Comment Andrew Camp Comment Poemen Chan & Clement Tham

IGR 19-3 | 2018

Opinion Challenges with deep learning in glaucoma IGR 19-3 | 2018

IGR 18-3 | 2017

On: Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice

Comment Keith Martin Comment Louis Pasquale Comment Harry Quigley Comment Derek Welsbie Response Pete Williams & Simon John

IGR 18-2 | 2017

On: Effectiveness of early lens extraction for the treatment of primary angle-closure glaucoma (EAGLE): a randomised controlled trial

Comment Rupert Bourne Comment Clement Tham Comment Benjamin Xu Response Jennifer Burr & Augusto Azuara Blanco

IGR 18-1 | 2017

On: Validity of the Monocular Trial of Intraocular Pressure-Lowering at Different Time Points in Patients Starting Topical Glaucoma Medication

Comment Kaweh Mansouri Comment Luciano Quaranta Comment Tony Realini Response Rotchfold & Anthony King

IGR 17-4 | 2016

On: Structural and Functional Progression in the Early Manifest Glaucoma Trial

Comment Chris Johnson Comment Tae-Woo Kim Comment Chris Leung Response Hanna Maria Öhnell

IGR 17-3 | 2016

On: Fast circulation of cerebrospinal fluid: an alternative perspective on the protective role of high intracranial pressure in ocular hypertension

Comment David Fleischman Comment Jost Jonas Response Peter Wostyn

IGR 16-3 | 2015

On: Short-Term Enhancement of Visual Field Sensitivity in Glaucomatous Eyes Following Surgical Intraocular Pressure Reduction

Comments Ivan Goldberg Comments Kaweh Mansouri Comments Shamira Perera Response David Greenfield

On: Induced pluripotent stem cells restore function in a human cell loss model of open-angle glaucoma

Comments Terete Borras Comments Yiqin Du Comments Michael Fautsch Comments Paul Kaufman Response Mary Kelley

Opinion Episcleral Venous Pressure IGR 16-3 | 2015

IGR 16-2 | 2015

Opinion Visual field testing in early glaucoma IGR 16-2 | 2015

IGR 16-1 | 2014

On: Glucose-induced temporary visual recovery in primary open-angle glaucoma: a double-blind, randomized study

Comments Jonathan Crowston Comments Jeffrey Goldberg Comments Keith Martin Response Robert Casson

Opinion Glaucoma Opinion: What is next for genetics and glaucoma? IGR 16-1 | 2014

IGR 15-4 | 2014

Opinion Glaucoma Opinion: The Role of Estrogen in Glaucoma IGR 15-4 | 2014

IGR 15-2 | 2013

On: Do findings on routine examination identify patients at risk for primary open-angle glaucoma? The rational clinical examination systematic review

Comments Esther Hoffmann Comments Tony Realini Comments George Spaeth Response Davin Johnson & Delan Jinapriya & Hussein Hollands

Opinion Glaucoma Opinion: A unifying concept for trabecular meshwork pathology in primary open-angle glaucoma IGR 15-2 | 2013

IGR 15-1 | 2013

On: Longitudinal hemodynamic changes within the optic nerve head in experimental glaucoma

Comments Alon Harris Comments Louis Pasquale Response Lin Wang

Opinion Glaucoma Opinion: ONH Biomechanics and Glaucoma: A Complicated Story IGR 15-1 | 2013

IGR 14-4 | 2013

Opinion Glaucoma Opinion: Prostaglandin-Associated Periorbitopathy (PAP): Clinical features, pathophysiology and implications for ophthalmologists IGR 14-4 | 2013

IGR 14-3 | 2013

On: Subspecialization in glaucoma surgery

Comments Keith Barton Comments Philippe Denis Comments Robert Feldman Comments Steven Gedde Comments Ivan Goldberg Comments Remo Susanna Jr Response Cambell

Opinion Glaucoma Opinion: We Must Do Better, Acquire Excellent MIGS Skills IGR 14-3 | 2013

IGR 14-2 | 2013

On: Reduction in Intraocular Pressure after Cataract Extraction: The Ocular Hypertension Treatment Study

Comments Keith Barton Comments Paul Healey Comments Fabian Lerner Comments Kuldev Singh Comments Clement Tham Response Steve Mansberger

IGR 14-1 | 2012

On: Cost-effectiveness of Medications Compared With Laser Trabeculoplasty in Patients With Newly Diagnosed Open-Angle Glaucoma

Comments Rupert Bourne Comments Ivan Goldberg Comments Kuldev Singh Comments Jeffrey Liebmann Response Josh Stein

Opinion Identification of Novel Genetic Loci for Primary IGR 14-1 | 2012

IGR 13-4 | 2012

On: Retinal Ganglion Cell Layer Thickness and Local Visual Field Sensitivity in Glaucoma

Comments Harry Quigley Comments David Garway-Heath Comments Chris Johnson Comments William Swanson Response Donald Hood

Opinion Immunity and Glaucoma IGR 13-4 | 2012 Opinion Immunity and Glaucoma IGR 13-4 | 2012

IGR 13-3 | 2011

On: Aqueous humor dynamics during the day and night in volunteers with ocular hypertension

Comments Paul Kaufman Comments Catherine Jui-Ling Liu Comments Tony Realini Comments Arthur Sit Response Carol Toris & Shan Fan & Vikas Gulati

Opinion Update on Glaucoma Genetics IGR 13-3 | 2011

IGR 13-2 | 2011

Opinion Exfoliation Syndrome IGR 13-2 | 2011

IGR 13-1 | 2011

On: A Randomized Trial of Brimonidine Versus Timolol in Preserving Visual Function: Results From the Low-pressure Glaucoma Treatment Study

Comments Tin Aung Comments Christopher Girkin Comments Ivan Goldberg Comments Chris Johnson Comments Harry Quigley Response Robert Ritch & David Greenfield & Jeffrey Liebmann & Stuart Gardiner & Theodore Krupin

Opinion Initiating Medical Therapy for Glaucoma IGR 13-1 | 2011

IGR 12-4 | 2011

On: Treating patients presenting with advanced glaucoma - Should we reconsider current practice?

Comments Keith Barton Comments George Spaeth Comments Chris Leung Comments Franz Grehn Comments Felipe Medeiros Comments Jeffrey Liebmann

Opinion Neurodegeneration in Glaucoma IGR 12-4 | 2011

IGR 12-3 | 2010

On: Transscleral diode laser cycloablation in patients with good vision

Comments Ravi Thomas Comments Fabian Lerner Comments Keith Barton Comments Kuldev Singh Comments Paul Palmberg Comments Tarek Shaarawy & Shibal Bhartiya Response Stephen Vernon & Rotchfold & Anthony King

Opinion Scope of glaucoma in India IGR 12-3 | 2010

IGR 12-2 | 2010

On: Adenoviral gene transfer of active human transforming growth factor-{beta}2 elevates intraocular pressure and reduces outflow facility in rodent eyes

Comments Terete Borras Comments Peng Tee Khaw Comments Hari Jayaram Comments Nils Loewen Comments Tina Wong Response Wan-Heng Wang & Nasreen Jacobson & Iok-hou Pang & J. Cameron Millar & Allan R. Shepard & Abbot Clark

Opinion The Ethics of Surgical Innovation IGR 12-2 | 2010

IGR 12-1 | 2010

On: Optical coherence tomography quantitative analysis of iris volume changes after pharmacologic mydriasis

Comments David Friedman Comments Jian Ge Comments Paul Healey Comments Jost Jonas Comments Robert Ritch Comments Ningli Wang Response Philippe Denis & Florent Aptel

Opinion Glaucoma Opinion: Gene Therapy in Glaucoma IGR 12-1 | 2010

IGR 11-4 | 2010

On: Three-year follow-up of the tube versus trabeculectomy study

Comments Ike Ahmed Comments Richard Lewis Comments Kouros Nouri-Mahdavi Comments Tarek Shaarawy Comments George Spaeth Comments Tina Wong Response Steven Gedde

Opinion Glaucoma: the African exception IGR 11-4 | 2010

IGR 11-3 | 2009

On: Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: Implications for glaucoma

Comments Makoto Aihara Comments Jeffrey Goldberg Comments Leonard A. Levin Comments James Morgan Comments Neville Osborne Comments Harry Quigley Response Lambiase

Opinion Advances in stem cell therapy for glaucoma IGR 11-3 | 2009

IGR 11-2 | 2009

On: Axonal regeneration induced by repetitive electrical stimulation of crushed optic nerve in adult rats

Comments Makoto Aihara Comments Jeffrey Goldberg Comments Leonard A. Levin Comments Keith Martin Comments Barbara Lorber Comments Manuel Vidal-Sanz & James Morgan Response Takuji Kurimoto

IGR 11-1 | 2009

On: Effect of brimonidine on retinal ganglion cell survival in an optic nerve crush model

Comments Makoto Aihara Comments David Calkins Comments Robert Casson Comments Ivan Goldberg Comments Keith Martin Comments Neville Osborne Response Jost Jonas

Opinion The scope of glaucoma in China IGR 11-1 | 2009

IGR 10-4 | 2009

On: Disc hemorrhages and treatment in the early manifest glaucoma trial

Comments Don Budenz Comments Kenji Kashiwagi Comments Chris Leung Comments James Morgan Comments Jody Piltz-Seymour Comments Hidenobu Tanihara Response Boel Bengtsson

Opinion Modeling the cost of POAG IGR 10-4 | 2009

IGR 10-3 | 2008

On: The additional yield of a periodic screening programme for open-angle glaucoma: A population-based comparison of incident glaucoma cases detected in regular ophthalmic care with cases detected during screening